This article is an erratum on:
Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
Frontiers Production Office*by Zhang L, Cai X, Peng F, Tian S, Wu X, Li Y and Guo J (2023). Front. Pharmacol. 14:1182644. doi: 10.3389/fphar.2023.1182644
Due to a production error, there was a mistake in Table 1 as published. The table erroneously contained references. The corrected Table 1 appears below.
TABLE 1
TABLE 1. Baseline information.
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: tigecycline, cefoperazone/sulbactam, carbapenems, β-lactam antibiotics, coagulation disorders, hypofibrinogenaemia
Citation: Frontiers Production Office (2024) Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies. Front. Pharmacol. 15:1365927. doi: 10.3389/fphar.2024.1365927
Received: 05 January 2024; Accepted: 05 January 2024;
Published: 15 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org